Product Images Levetiracetam
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Levetiracetam NDC 43598-759 by Dr.reddy's Laboratories Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a description for Levetiracetam in 0.75% Sodium Chloride Injection for Intravenous Infusion Only, produced by novaplus. The rest of the text contains errors and is not readable.*
This is a description of a medication called Levetiracetam in 0.54% Sodium Chloride Injection, with a concentration of 1,500 mg/100 mL (15 mg/m). It is intended for intravenous infusion only and is produced by Novaplus.*
This appears to be a label for a medication called Levetiracetam that is mixed with Sodium Chloride Injection for infusion through veins at a specific dosage. It is recommended for intravenous use only. There is also mention of dosage bags made by NovaPlus.*
This appears to be a chart or table displaying percentages and statistical significance. It is related to the administration of two drugs, Levtiacram and Levetracetam, at different dosages, and their impact on an unspecified number of patients. However, it is difficult to provide additional context or understanding without further information or the ability to read the text more accurately.*
The text describes the results of a study comparing the effectiveness of a placebo versus two different doses of a medication called Levetiracetam in the treatment of a medical condition. The number of patients in each group is provided, as well as the dosage of the medication being taken. The text notes that the medication was found to be statistically significant in its effectiveness when compared with the placebo.*
This is a summary of a statistical analysis involving two groups of patients given a placebo and Lovetiracatam. The first group showed a success rate of 72.2%, while the second group achieved a success rate of 45.2%. The number of patients involved was three. The analysis indicated Lovetiracatam had a statistically significant effect compared to the placebo.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.